Robert L. Zerbe M.D. is Director at Vericel Corp (VCEL). They have made 2 open-market trades across 1 company since 2020, most recently 2026-04-29.
CIK 0001220363
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VCEL | SELL · 10b5-1 | 2025-02-05 | 2025-02-07 | $62.50 | $156K | -6.7% | -16.1% | -28.1% |
| VCEL | SELL · 10b5-1 | 2024-11-22 | 2024-11-25 | $60.00 | $150K | -3.5% | -1.3% | -10.4% |
| VCEL | SELL · 10b5-1 | 2024-11-11 | 2024-11-13 | $56.25 | $281K | +5.4% | +3.3% | +3.4% |
| VCEL | SELL · 10b5-1 | 2024-03-27 | 2024-03-29 | $51.57 | $338K | -6.5% | -11.3% | -10.8% |
| VCEL | SELL · 10b5-1 | 2024-02-20 | 2024-02-22 | $50.01 | $36K | -7.9% | -0.7% | +4.3% |
| VCEL | SELL | 2024-01-29 | 2024-01-30 | $44.22 | $102K | +6.4% | +3.9% | +6.1% |
| VCEL | SELL · 10b5-1 | 2024-01-25 | 2024-01-29 | $44.02 | $9K | +4.7% | +9.1% | +6.5% |
| VCEL | SELL · 10b5-1 | 2024-01-22 | 2024-01-24 | $41.90 | $461K | -0.4% | +9.0% | +6.9% |
| VCEL | SELL · 10b5-1 | 2024-01-12 | 2024-01-16 | $38.09 | $168K | +9.9% | +27.4% | +25.7% |
| VCEL | SELL · 10b5-1 | 2023-11-15 | 2023-11-17 | $38.02 | $11K | -2.0% | -5.5% | +36.1% |
| VCEL | SELL · 10b5-1 | 2023-07-14 | 2023-07-17 | $38.84 | $39K | -3.2% | -16.9% | -13.5% |
| VCEL | SELL · 10b5-1 | 2023-06-22 | 2023-06-26 | $36.00 | $108K | -1.9% | +3.8% | -6.6% |
| VCEL | SELL | 2020-11-23 | 2020-11-24 | $23.55 | $412K | +9.0% | +23.9% | +107.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.